Priorities in Parkinson's disease research
Wassilios G. Meissner(Centre National de la Recherche Scientifique), Erwan Bézard(Centre National de la Recherche Scientifique), David M. Weiner(Ono Pharmaceutical (United States)), Paola Piccini(Hammersmith Hospital), Olivier Rascol(Inserm), Anthony H.V. Schapira(National Hospital for Neurology and Neurosurgery), José Á. Obeso(Instituto de Salud Carlos III), Thomas Gasser(Hertie Institute for Clinical Brain Research), Andrés M. Lozano(University of Toronto), Valerie Voon(University of Cambridge), Mark Frasier(Michael J. Fox Foundation), François Tison(Institut des Maladies Neurodégénératives), Christopher G. Goetz(Rush University Medical Center)
Cited by 430
Related Papers
MDS clinical diagnostic criteria for Parkinson's disease
|Movement Disorders|2015|7.4k
Deep Brain Stimulation for Treatment-Resistant Depression
|Neuron|2005|4.1k
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
|Movement Disorders|2017|2.3k
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
|New England Journal of Medicine|2009|2.1k
Genome-wide association study reveals genetic risk underlying Parkinson's disease
|Nature Genetics|2009|2k